- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01634230
Emergency Use of OCR-002 in Acute Liver Failure (ALF)
June 18, 2021 updated by: Ocera Therapeutics, Inc.
Emergency Use of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure
This study provides emergency use of the unapproved study medication in ALF patients with acute liver failure who are not responding to standard of care.
Study Overview
Detailed Description
This is an open-label study in patients diagnosed with ALF who are not responding to the institution's standards of care.
Standard of care may include, but is not limited to, administration of N-acetylcysteine, lactulose, hypothermia therapy, and consideration for orthotopic liver transplant.
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
- Treatment IND/Protocol
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- International Normalized Ratio (INR) ≥1.5 with encephalopathy in patient with no prior history of liver disease
- Venous ammonia level of ≥ 100 μmol/L
Exclusion Criteria:
- Patients who are pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Global Clinical Leader, Ocera Therapeutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
June 25, 2012
First Submitted That Met QC Criteria
July 2, 2012
First Posted (Estimate)
July 6, 2012
Study Record Updates
Last Update Posted (Actual)
June 24, 2021
Last Update Submitted That Met QC Criteria
June 18, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OCR002-EmUse-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Liver Failure
-
HLB Cell Co., Ltd.UnknownAcute-On-Chronic Liver Failure | Acute Liver FailureKorea, Republic of
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWithdrawnAcute-On-Chronic Liver Failure | Acute Liver FailureChina
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver Failure | Acute on Chronic Liver FailureIndia
-
Beijing Continent Pharmaceutical Co, Ltd.RecruitingAcute-On-Chronic Liver Failure | Acute Liver FailureChina
-
Chulalongkorn UniversityRecruitingAcute-On-Chronic Liver Failure | Acute on Chronic Hepatic FailureThailand
-
Tianjin Weikai Bioeng., Ltd.Tianjin Nankai HospitalUnknownLiver Failure, Acute on ChronicChina
-
University of EdinburghNHS LothianNot yet recruitingAcute on Chronic Hepatic Failure | Acute Liver Failure | Acute Liver Injury
-
Nanfang Hospital of Southern Medical UniversityCompletedLiver Injury | Liver Failure, Acute on Chronic
-
Aga Khan UniversityNational Institute of Liver & GI Diseases, PakistanNot yet recruiting
Clinical Trials on OCR-002
-
Ocera Therapeutics, Inc.Completed
-
Hospital Universitari Vall d'Hebron Research InstituteCompletedCirrhosis | Gastrointestinal BleedingSpain
-
William LeeMedical University of South Carolina; National Institute of Diabetes and Digestive... and other collaboratorsCompletedAcute Liver Failure | Acute Liver InjuryUnited States
-
Ocera Therapeutics, Inc.CompletedHepatic Encephalopathy | Acute Episode of Overt Hepatic EncephalopathyBelgium, Germany, Italy, Spain, United States, France, Austria, Russian Federation, Czechia, Australia, Hungary, Israel, Netherlands, Bulgaria, Estonia, Denmark, New Zealand
-
Avalo Therapeutics, Inc.CompletedNon-Eosinophilic AsthmaUnited States
-
Aevi Genomic Medicine, LLC, a Cerecor companyCompletedAcute Lung Injury | ARDS | COVID-19 PneumoniaUnited States
-
Avalo Therapeutics, Inc.TerminatedCrohn Disease | Ulcerative ColitisUnited States
-
Vyluma, Inc.Syneos HealthActive, not recruitingMyopiaUnited States, Hungary, Ireland, Netherlands, Spain, United Kingdom
-
BiocadRecruitingStudy of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)Hemophilia BRussian Federation
-
PMG Pharm Co., LtdRecruitingKnee OsteoarthritisKorea, Republic of